OPKO Health (OPK) Scheduled to Announce Earnings on Thursday

OPKO Health (NASDAQ:OPK - Get Free Report) will post its quarterly earnings results after the market closes on Thursday, November 7th. Analysts expect OPKO Health to post earnings of ($0.10) per share for the quarter. Individual interested in registering for the company's earnings conference call can do so using this link.

OPKO Health (NASDAQ:OPK - Get Free Report) last announced its quarterly earnings results on Wednesday, August 7th. The biotechnology company reported ($0.01) earnings per share for the quarter, topping analysts' consensus estimates of ($0.09) by $0.08. The company had revenue of $182.20 million for the quarter, compared to analysts' expectations of $184.70 million. OPKO Health had a negative net margin of 33.79% and a negative return on equity of 17.67%. The business's quarterly revenue was down 31.3% compared to the same quarter last year. During the same period last year, the firm posted ($0.03) earnings per share. On average, analysts expect OPKO Health to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

OPKO Health Trading Down 0.7 %

OPKO Health stock traded down $0.01 during mid-day trading on Thursday, hitting $1.51. 1,684,321 shares of the company's stock were exchanged, compared to its average volume of 7,083,401. The company's 50 day simple moving average is $1.54 and its 200-day simple moving average is $1.41. The company has a quick ratio of 1.36, a current ratio of 1.63 and a debt-to-equity ratio of 0.13. The firm has a market capitalization of $1.05 billion, a P/E ratio of -4.30 and a beta of 1.63. OPKO Health has a fifty-two week low of $0.85 and a fifty-two week high of $1.75.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on the company. HC Wainwright reiterated a "buy" rating and set a $3.00 price objective on shares of OPKO Health in a report on Thursday, September 26th. Barrington Research reaffirmed an "outperform" rating and issued a $2.25 price target on shares of OPKO Health in a research note on Friday, September 20th. Piper Sandler reissued an "overweight" rating and set a $3.00 price objective on shares of OPKO Health in a research report on Tuesday, September 17th. Finally, StockNews.com raised shares of OPKO Health to a "sell" rating in a research report on Saturday, July 27th.

Insider Activity

In related news, major shareholder Opko Health, Inc. sold 100,000 shares of OPKO Health stock in a transaction dated Thursday, August 8th. The shares were sold at an average price of $31.82, for a total transaction of $3,182,000.00. Following the completion of the sale, the insider now owns 2,871,570 shares of the company's stock, valued at approximately $91,373,357.40. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders sold a total of 262,605 shares of company stock valued at $8,635,020 over the last three months. Insiders own 47.26% of the company's stock.

OPKO Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.